| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 03/12/2024 | 14:38 | Business Wire | Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds | NASDAQ:REVB | Revelation Biosciences Inc |
| 02/12/2024 | 12:00 | Business Wire | Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND | NASDAQ:REVB | Revelation Biosciences Inc |
| 12/11/2024 | 12:00 | Business Wire | Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply | NASDAQ:REVB | Revelation Biosciences Inc |
| 08/11/2024 | 22:15 | Business Wire | Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024 | NASDAQ:REVB | Revelation Biosciences Inc |
| 24/09/2024 | 12:00 | Business Wire | Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10 | NASDAQ:REVB | Revelation Biosciences Inc |
| 03/09/2024 | 23:09 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:REVB | Revelation Biosciences Inc |
| 26/08/2024 | 22:25 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:REVB | Revelation Biosciences Inc |
| 21/08/2024 | 23:30 | Business Wire | Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds | NASDAQ:REVB | Revelation Biosciences Inc |
| 09/08/2024 | 22:15 | Business Wire | Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024 | NASDAQ:REVB | Revelation Biosciences Inc |
| 29/07/2024 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:REVB | Revelation Biosciences Inc |
| 24/06/2024 | 15:00 | Business Wire | Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity | NASDAQ:REVB | Revelation Biosciences Inc |
| 13/06/2024 | 15:21 | Business Wire | Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini | NASDAQ:REVB | Revelation Biosciences Inc |
| 10/05/2024 | 22:52 | Business Wire | Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024 | NASDAQ:REVB | Revelation Biosciences Inc |
| 22/03/2024 | 21:15 | Business Wire | Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023 | NASDAQ:REVB | Revelation Biosciences Inc |
| 13/03/2024 | 14:00 | Business Wire | Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024) | NASDAQ:REVB | Revelation Biosciences Inc |
| 12/03/2024 | 14:00 | Business Wire | Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference | NASDAQ:REVB | Revelation Biosciences Inc |
| 04/03/2024 | 15:00 | Business Wire | Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini | NASDAQ:REVB | Revelation Biosciences Inc |
| 14/02/2024 | 02:12 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:REVB | Revelation Biosciences Inc |
| 13/02/2024 | 15:00 | Business Wire | Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) | NASDAQ:REVB | Revelation Biosciences Inc |
| 12/02/2024 | 16:19 | Edgar (US Regulatory) | Form SCHEDULE 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:REVB | Revelation Biosciences Inc |
| 05/02/2024 | 22:41 | Business Wire | Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering | NASDAQ:REVB | Revelation Biosciences Inc |
| 02/02/2024 | 22:06 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] | NASDAQ:REVB | Revelation Biosciences Inc |
| 01/02/2024 | 12:00 | Business Wire | Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering | NASDAQ:REVB | Revelation Biosciences Inc |
| 30/01/2024 | 21:32 | Edgar (US Regulatory) | Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] | NASDAQ:REVB | Revelation Biosciences Inc |
| 30/01/2024 | 15:00 | Business Wire | Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) | NASDAQ:REVB | Revelation Biosciences Inc |
| 23/01/2024 | 15:00 | Business Wire | Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024 | NASDAQ:REVB | Revelation Biosciences Inc |
| 22/12/2023 | 23:06 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NASDAQ:REVB | Revelation Biosciences Inc |
| 22/12/2023 | 19:23 | Edgar (US Regulatory) | Form S-1 - General form for registration of securities under the Securities Act of 1933 | NASDAQ:REVB | Revelation Biosciences Inc |
| 12/12/2023 | 22:59 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements | NASDAQ:REVB | Revelation Biosciences Inc |
| 13/11/2023 | 22:05 | Business Wire | Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023 | NASDAQ:REVB | Revelation Biosciences Inc |